. 2017 Apr 12;2(1):e000101. doi: 10.1136/esmoopen-2016-000101

Table 1.

Case series overview: clinical presentation, treatment modality, best tumour marker, radiological response and time to progression*.

Case	Age	Clinical presentation	Line of treatment	Treatment type	Best CA-125 response	Best radiological response	TTP (mo)	Time from diagnosis to last follow-up (mo)
1	28	Abdominalpain and 15 cm pelvic mass	1^st	Optimal tumour debulking, 4 cis-pem, pelvic RT and brachytherapy	NK	SD	23
			2^nd	Surgery, 4 cis-pem	NK	SD	30
			3^rd	8 carbo-pem	38→21	SD	17
			4^th	2.8 years PI3K-mTOR inhibitor	217→32	cPR	34
			5^th	6 mo PARP-AKT inhibitor	200→69	SD	AWD	156
2	19	Vaginal bleeding, abdominal pain and distension	1^st	4 cis-pem	NK	SD	35
			2^nd	4 cis-pem	NK	SD	11
			3^rd	2 mo HDAC inhibitor	NK	SD	5
			4^th	15 mo PI3K-mTOR inhibitor	200→172	SD	AWD	123

*TTP, time to progression; mo, months; SD, stable disease; cPR, confirmed partial response; AWD, alive with disease; RT, radiotherapy; cis, cisplatin; carbo, carboplatin; pem, pemetrexed; PI3K, phosphatidyl-3-kinase; mTOR, mammalian target of rapamycin; PARP, poly(ADP)-ribose polymerase; HDAC, histone deacetylase; NK, not known.